Key Takeaways
- Record revenue, margin squeeze: Revenue hit an all-time high, but gross margin fell 4% QoQ to 49% as the West Asia crisis drove up raw material, reagent, and solvent costs that could not be fully passed on.
- PI/API segment turns a corner: Management pushed back on the "volatility" narrative, pointing to a sequential ramp-up over the last three to four quarters, with a strong order book ahead.
- Capacity build-out is on track: Mahad Unit 3 for a strategically critical KSM remains on schedule for H2, Vizag Phase I pre-construction is underway, and the Hyderabad R&D center is operational with ~50 scientists onboarded.
- Pricing relief is in motion, not yet in the P&L: Customer discussions on passing through reagent and solvent price increases have begun, with select increases effective from Q3; the net margin impact depends on input price movement and mix.
- What to watch next quarter: Whether the Q3 price increases actually lift gross margins, the pace of Vizag Phase I construction, and any commercial progress on the two clinical-stage innovator molecules.
Revenue & Segment Performance
- Record top line: The quarter delivered the highest-ever revenue, driven by improved momentum across both core businesses.
- PI/API segment: Growth was led by the existing portfolio plus a new molecule; the bulk of H1 revenue came from commercial products, with a smaller contribution from incubated or clinical-stage products. Management stated the segment has seen sequential ramp-up over the last three to four quarters and is expected to be a growth driver going forward.
- Contrast media: The segment maintained healthy momentum, supported by established customer relationships and an expanding product portfolio. Volume growth is present, with a very small impact from volume discounts; from a production perspective, the segment is reasonably constant and existing volumes are being sustained.
- Oncology and CNS products: These are now commercial and form part of the PI vertical, with commercial quantities supplied during the quarter.
- No granular breakdown: Management declined to split revenue growth between volume recovery from existing products and new molecules, stating it would not provide product-level quantity and value detail.
V.K. Singh: "I do not think it is right to say that there has been a lot of volatility for the previous several quarters. I would say for the last three to four quarters, there has been sequential ramp-up."
Margins & Raw Material Headwinds
- Gross margin compression: Q2 gross margin fell 4% QoQ to 49%, and H1 FY27 gross margin fell 3% YoY to 51%, because the West Asia crisis increased prices of raw materials, reagents, and solvents across the board. The timing of purchases, inventory consumption, and in-transit stock affects when higher costs flow through the P&L.
- Pass-through asymmetry: While some raw material price increases could be passed to customers, reagents and solvents could not be passed on 100%. The impact varies by product depending on the input procured and the pricing terms under each customer agreement.
- H1 EBITDA and PAT: Grew in absolute terms but saw a marginal percentage reduction because of headcount additions and certain logistics costs.
- Pricing actions underway: Discussions with customers on passing through reagent and solvent price increases have already started; price increases with select customers will come into force from Q3. Management expects a positive impact on gross margin percentage in coming quarters, though the net impact depends on how input prices move, product mix, and when customer price adjustments become effective.
- Crude-linked outlook: If crude remains at current levels, Q2 gross margins should be a reasonable estimate going forward; management cannot guesstimate crude price behavior or linked chemical prices.
Ganesh Karuppannan: "This West Asia crisis has resulted in increase in raw material price across board. Not only raw materials, you can take any reagent, any solvent, everything has gone up. ... when it comes to reagents and solvent, you cannot actually pass on 100% of the price increase."
Capacity Expansion & R&D Build-Out
- Mahad Unit 3: The facility for a strategically critical KSM in the contrast media business remains on track to go on stream in the second half of this year.
- Vizag Phase I: Pre-construction activities are underway; statutory compliances including Environmental Clearance and Consent to Establish are in place. Investment is being approached in a phased and disciplined manner, with capacity planning closely aligned to identified customer opportunities and the progression of the development pipeline. The vision is to create a manufacturing platform capable of supporting multiple chemistry technologies, customers, and product life cycles.
- Hyderabad R&D center: Now operational with scientific teams onboarded and development activities underway. The facility houses several synthesis labs and a world-class analytical facility, with approximately 50 high-performing scientists onboarded. It will bring platform diversification including flow synthesis, peptides, GLP-related intermediates, biocatalysis, high-potency products, and solid-phase chemistry, strengthening the ability to address innovator-led programs and improve response time to increasing RFPs.
- Lateral entry timing: The lateral entries will come from Vizag Phase I, which is "some time away." If bridging capacities are needed, current capacities may be used, but the main bulk of volumes will come when Vizag is on stream.
- QIP deployment: The successful qualified institutional placement will be phased over the next three years for capital expenditure, partly for working capital, and general corporate purpose.
Shiven Arora: "Our ambition is not simply to add manufacturing capacity. We are building a globally competitive CDMO platform that combines decades of complex chemistry expertise with integrated R&D, flexible manufacturing infrastructure, and long-standing relationships with global pharmaceutical innovators."
Innovator-Led Pipeline & New Molecules
- New contrast media intermediate: Successfully delivered and validated for an innovator; the molecule is an NCE still in the clinical phase. Management called the opportunity "very credible" but noted it must still go through regulatory and commercial phases.
- Peptide fragment: Progress made with an innovator company on a late-phase clinical molecule. Current supplies are all trial or validation quantities; management said it is too premature to comment on asset turns for peptides and does not recommend extrapolating historical asset turns as they are too high to maintain.
- Peptide strategy: The focus is on fragments (intermediates in peptides). If customers want, the company will forward integrate toward the finished product, including the final peptide, and will build capability and capacity for that. The R&D capability being set up will first be for liquid-phase synthesis; at the fragment level, liquid-phase or solid-phase synthesis is not needed, that comes when condensing chains to form the final peptide.
- Clinical-stage molecules: The two molecules in clinical phases will take a while to launch and reach commercial stage.
- Forward integration in contrast media: When the company moves to the next forward integration step (the iodination step), there will be a significant jump in revenue realization and margins; quantification will come later.
V.K. Singh: "That the final API will be a better opportunity than intermediates is not always true. ... If our customers want, we will be more than happy to forward integrate from the intermediates and fragments and peptide side also, and go more and more towards the finished product, maybe including the final peptide, for which we will build and have capability and capacity."
Vizag & Sweeteners
- Capacity anchored by existing clients: The Vizag capacity is being anchored by existing clients with firm commitments. The new high-intensity sweetener is a portfolio addition, different from the current product, and very few in India make it. Management is very confident the capacities will get engaged very quickly with very low gestation, since it is an adjacency that will go to existing clients without needing to discover any new market.
- GLP-1 and peptide capex allocation: When asked how much of the Vizag capex is tied to GLP-1 and peptides, management answered about priorities (CDMO platform, contrast media, sweeteners, fragments) but did not provide a capex allocation figure.
V.K. Singh: "Very few people, particularly none in India, make that. We are very confident that since it is an adjacency, it will go to our existing clients. We do not have to discover any new market. We are very confident that the capacities that we set up will get engaged very quickly with a very low gestation."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Gross margin recovery | Price increases with select customers come into force; positive impact expected, net effect depends on input prices and mix | From Q3 FY27 (positive impact expected in coming quarters) |
| Mahad Unit 3 on stream | Facility for strategically critical KSM in contrast media business | H2 FY27 |
| QIP deployment | Phased over three years for capex, working capital, and general corporate purpose | Over next 3 years |
| Vizag Phase I lateral entries | Main bulk of volumes to come when Vizag is on stream | "Some time away" (no date) |
| Clinical-stage molecules launch | Two molecules in clinical phases to reach commercial stage | "Will take a while" (no date) |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹375 cr, +28% QoQ; highest-ever quarterly revenue |
| EBITDA | ₹119 cr, 32% of operating revenue, -1 ppt QoQ |
| Profit after tax | ₹103 cr, 27% of total income, flat QoQ |
| Gross margin | 49%, -4 ppt QoQ; raw material price increases from West Asia crisis |
| H1 FY27 revenue | ₹669 cr, +29% YoY |
| H1 FY27 EBITDA | ₹217 cr, 32% of operating income, -2 ppt YoY |
| H1 FY27 PAT | ₹181 cr, 27% of total income, -1 ppt YoY |
| Contrast media revenue growth | +25% QoQ |
| PI API revenue growth | +52% QoQ |
| Artificial sweetener revenue growth | -30% QoQ |
| Mahad Unit 3 capex incurred to date | ~₹250 cr |
| Vizag Phase I envisaged capex | ~₹1,000 cr |
| Hyderabad R&D scientists onboarded | ~50 |
| Renewable energy share of consumption | ~80% |
| QIP raise | ₹800 cr, deployment phased over three years |